Rational Second-Generation Antiandrogen Use in Prostate Cancer.

Jacob J Orme, Lance C Pagliaro, J Fernando Quevedo, Sean S Park, Brian A Costello

The oncologist 2022 Mar 04

filter terms:

The second-generation antiandrogens have achieved an ever-growing list of approvals and indications in subsets of prostate cancer. Here, we provide an overview of second-generation antiandrogen trials and FDA approvals and outline a rational sequencing approach for the use of these agents as they relate to chemotherapy and other available treatment modalities in advanced prostate cancer. All published phase II-III randomized controlled trials reporting outcomes with the use of second-generation antiandrogens in prostate cancer are included as well as all published trials and retrospective studies of second-generation antiandrogen sequencing and/or combinations. Complete tabular and graphical representation of all available evidence is provided regarding the use and sequencing of second-generation antiandrogens in prostate cancer. In metastatic castration-resistant prostate cancer, evidence suggests prioritization of abiraterone before chemotherapy, chemotherapy after second-generation antiandrogen failure, and postchemotherapy enzalutamide in select patients to maximize agent efficacy and tolerability. We conclude that a rational, optimized sequencing of second-generation antiandrogens with other treatment options is feasible with present data. © The Author(s) 2022. Published by Oxford University Press.

Citation

Jacob J Orme, Lance C Pagliaro, J Fernando Quevedo, Sean S Park, Brian A Costello. Rational Second-Generation Antiandrogen Use in Prostate Cancer. The oncologist. 2022 Mar 04;27(2):110-124